secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0000950170-24-096172
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Korro Bio Q2 net loss $21.8M; cash $187.8M; KRRO-110 FIH filing on track
------------------------------------------------------------------------

- Net loss of $21.8M for Q2 2024, up from $17.6M in Q2 2023, driven by higher R&D and G&A costs.
- Cash, equivalents & marketable securities total $187.8M as of June 30, 2024; runway into H2 2026.
- Regulatory filing for KRRO-110 first-in-human trial in AATD expected in H2 2024.
- Preclinical data showed >70% M-AAT protein in circulation with ~60% sustained editing efficiency.
- Completed $70M private placement in April 2024 to support pipeline development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000095017024096172/0000950170-24-096172-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000095017024096172/krro-20240813.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-096172

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer